Last update 04 Nov 2024

Bevacizumab biosimilar (Betta Pharma)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab biosimilar, MIL 60, MIL-60
+ [1]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fallopian Tube Carcinoma
CN
04 Mar 2022
Glioblastoma
CN
04 Mar 2022
Ovarian Cancer
CN
04 Mar 2022
Primary peritoneal carcinoma
CN
04 Mar 2022
Uterine Cervical Cancer
CN
04 Mar 2022
Colorectal Cancer
CN
24 Nov 2021
Non-Small Cell Lung Cancer
CN
24 Nov 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
15 Aug 2017
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
15 Aug 2017
Metastatic Colorectal CarcinomaPhase 1
CN
08 Nov 2016
Metastatic Colorectal CarcinomaPhase 1
CN
08 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
517
jwvkwnsamf(dnmekslyko) = jgtzakezlj ytkwgujyly (muuwckkxuz )
Positive
01 Dec 2021
jwvkwnsamf(dnmekslyko) = rkkregbgiz ytkwgujyly (muuwckkxuz )
Phase 3
517
Paclitaxel+Carboplatin+MIL60
zgywmdpetv(sodceppjnz) = smbscatrcc ybvhmvlcef (hixsurtjrp )
Similar
16 Sep 2021
Paclitaxel+Carboplatin+Bevacizumab+MIL60
zgywmdpetv(sodceppjnz) = cvfcodxxwb ybvhmvlcef (hixsurtjrp )
Pubmed
ManualManual
Phase 1
-
-
iqyaugomgt(hhxqdtbxcb) = Bevacizumab demonstrated linear PK properties and a concentration-dependent disposition. When comparing the three biosimilars with bevacizumab-EU, the 90% CIs of the ratios for Cmax, AUC0-t, and AUC0-∞ were within 80-125%. The inter-CV ranged from 12.6 to 23.3%. wqvvpsyutl (acowankruk )
Positive
01 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free